Compare LWAY & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LWAY | HELP |
|---|---|---|
| Founded | 1986 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.2M | 366.7M |
| IPO Year | 1995 | N/A |
| Metric | LWAY | HELP |
|---|---|---|
| Price | $21.23 | $5.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $35.00 | ★ $95.00 |
| AVG Volume (30 Days) | 29.5K | ★ 974.9K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $103,350,000.00 | N/A |
| Revenue This Year | $15.23 | N/A |
| Revenue Next Year | $13.72 | N/A |
| P/E Ratio | $28.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.50 | $5.27 |
| 52 Week High | $34.20 | $8.55 |
| Indicator | LWAY | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 38.98 | 36.56 |
| Support Level | $21.09 | N/A |
| Resistance Level | $22.70 | $7.28 |
| Average True Range (ATR) | 0.61 | 0.70 |
| MACD | -0.04 | -0.10 |
| Stochastic Oscillator | 6.52 | 2.74 |
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir which is a cultured dairy product. Its product categories are Drinkable Kefir which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir and Other dairy. The company manufacture and market products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through direct sales force, brokers, and distributors.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.